LONG-TERM UNDETECTABLE PLASMA HIV-1 RNA
$0M01FY2000RRNIH
Tulane University Of Louisiana, New Orleans LA
Investigators
Linked publications & trials
Paper 27803104Paper 26770763Paper 25648541Paper 25401485Paper 25109932Paper 24925880Paper 24613295Paper 24516231Paper 24415732Paper 24271347Paper 24219913Paper 24046302Paper 23727086Paper 23677024Paper 23619080Paper 23419804Paper 23349510Paper 23269790Paper 23076013Paper 23068916Paper 22981277Paper 22867730Paper 22853972Paper 22658574Paper 22554719Paper 22497791Paper 22483359Paper 22480598Paper 22465315Paper 22446176Paper 22019225Paper 22019221Paper 21985788Paper 21921144Paper 21904395Paper 21896829Paper 21783289Paper 21742304Paper 21705121Paper 21673295Paper 21554737Paper 21525746Paper 21396623Paper 21389978Paper 21382989Paper 21350366Paper 21239359Paper 20930087Paper 20929989Paper 20861271Paper 20847142Paper 20825306Paper 20822371Paper 20660819Paper 20618702Paper 20533872Paper 20531015Paper 20511979Paper 20399927Paper 20389058Paper 20173677Paper 20123264Paper 20019670Paper 19541818Paper 19395280Paper 19366774Paper 19200445Paper 19194319Paper 19000014Paper 18663165Paper 18593763Paper 18577469Paper 18413195Paper 18401832Paper 18227407Paper 18226670Paper 18215978Paper 18205225Paper 18191094Paper 18173357Paper 18025875Paper 18024536Paper 17978591Paper 17935800Paper 17682123Paper 17651776Paper 17623996Paper 17610099Paper 17599428Paper 17582655Paper 17509588Paper 17456892Paper 17451422Paper 17407044Paper 17389292Paper 17387446Paper 17258320Paper 17255739Paper 17230416Paper 17213921
Abstract
HIV infection weakens the immune system's ability to fight infections by destroying a special type of white blood cell called CD4 cells. The main purpose of this study is to find out if subjects with better immune systems before starting Highly Active Antiretroviral Therapy (HAART) do better than those who have weaker immune systems before starting HAART. This study will seek to determine if there is a positive correlation between baseline immunlogic status and the subsequent immunologic and virologic responses to HAART 1, 2, and 3 years after beginning treatment which will allow stratification for the initial viral load.
View original record on NIH RePORTER →